Insights from 2023 ASCO® Annual Meeting
Playback speed
10 seconds
ASCO® 2023 Insights: "lidERA Breast Cancer Phase III Adjuvant Study - Giredestrant vs. Physician’s Choice of ET for ER+/HER2- eBC"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Charles Geyer
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Charles Geyer
345 views
June 14, 2023
Comments 1
Login to view comments.
Click here to Login
Breast